NCT04462952 is a Phase 1 clinical trial of Adavosertib (AZD1775) in Advanced Solid Tumours, sponsored by AstraZeneca.

Who is sponsoring NCT04462952?

NCT04462952 is sponsored by AstraZeneca.

What drugs are being tested in NCT04462952?

Interventions in NCT04462952: Adavosertib (AZD1775).

What condition does NCT04462952 study?

NCT04462952 studies Advanced Solid Tumours.

Is NCT04462952 still recruiting?

NCT04462952 is currently completed. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT04462952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Completed Phase 1 Last updated 25 July 2022

What this trial tests

Phase 1 trial testing Adavosertib (AZD1775) in Advanced Solid Tumours in 6 participants. Completed in 22 September 2021.

Timeline

24 June 2020

Primary endpoint
22 September 2021

22 September 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	other
Enrollment	6
Start date	24 June 2020
Primary completion	22 September 2021
Estimated completion	22 September 2021
Sites	1 location across Japan

Drugs / interventions tested

Adavosertib (AZD1775) — full drug profile →

Conditions studied

Advanced Solid Tumours — all drugs for Advanced Solid Tumours →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 20 to 120, any sex, with Advanced Solid Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 parts, monotherapy (part A) and chemotherapy combination (part B). At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort to confirm the tolerability.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

DNA Repair Pathways in Cancer Therapy and Resistance.
Li LY, Guan YD, Chen XS, Yang JM, et al · · 2020 · cited 254× · PMID 33628188 · DOI 10.3389/fphar.2020.629266
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers.
Wu CE, Pan YR, Yeh CN, Lunec J. · · 2020 · cited 34× · PMID 33113997 · DOI 10.3390/biom10111474
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders.
Alli VJ, Yadav P, Suresh V, Jadav SS. · · 2023 · cited 18× · PMID 37323408 · DOI 10.1021/acsomega.3c01558
Targeting the DNA damage response in cancer.
Federica G, Michela C, Giovanna D. · · 2024 · cited 12× · PMID 39492835 · DOI 10.1002/mco2.788
Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
Kondo S, Katsuya Y, Yonemori K, Komuro K, et al · · 2024 · cited 2× · PMID 38593512 · DOI 10.1016/j.ctarc.2024.100809
Synthetic Lethality-Based Targets and Their Exploration in Tumour Combination Strategies.
Wu L, Deng Y, Lei Z, Wang Y, et al · · 2025 · cited 1× · PMID 40859871 · DOI 10.1111/jcmm.70756

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumours

Currently open trials in the same condition.

NCT06868199 — A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06795412 — Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06815575 — A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. · Phase 1 · recruiting
NCT05701527 — A Study of EBC-129 in Advanced Solid Tumours · Phase 1 · recruiting
NCT06927349 — A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors. · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04462952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04462952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing